Technology
CURE Pharmaceutical Holding Corp.(CURR)
Live Price
Offline$3.03
+1.68% today
1Y Change
+404.19%
Window
Jun 25, 2025 → Jun 16, 2026
- Market Cap
- $270.00M
- Revenue Growth
- -18.6%
- EPS Growth
- +70.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars · Jun 25, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CURE Pharmaceutical Holding Corp. (CURR) is a Technology stock with a market cap of $270.00M and listed on NASDAQ. The stock last traded around $3.03 and up 404.2% across the available one-year price window (Jun 25, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -18.6%, EPS growth of +70.9%, a dividend yield of 0.0%. What stands out right now is revenue -18.6%, EPS +70.9%, free cash flow +157.0% with operating margin -21.0% and ROIC -21.9%. Valuation sits in the middle of the pack at price/sales 7.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CURR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-18.6% vs +11.9% peer median
Operating Margin
Below sector median
-21.0% vs +22.0% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -18.6% and EPS is at +70.9%, with operating margin around -21.0%.
Benchmark Edge
CURR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CURR
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CURR Max Drawdown
-63.49%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CURR and SPY.
Company Overview
CURE Pharmaceutical Holding Corp.
NASDAQ
Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on the development and commercialization of innovative drug delivery systems. It aims to improve patient adherence and experience by providing new methods for drug delivery, such as oral thin films and transdermal systems. Cure Pharmaceutical's technologies are designed to enhance the bioavailability, efficacy, and safety of existing pharmaceutical compounds while also providing a platform for new drug formulations. This plays a vital role in several therapeutic areas, including pain management, oncology, and central nervous system disorders. By leveraging cutting-edge technology and partnerships within the pharmaceutical industry, Cure Pharmaceutical Holding Corp. contributes to the advancement of personalized and precision medicine, addressing unmet medical needs and broadening the spectrum of delivery options in healthcare markets.
- Leadership
- Mr. King Ong Kong
- Employees
- 244
- Street Address
- 410 North Bridge Road, Spaces City Hall
- Mailing
- Singapore, NY, 188726
- Region
- Singapore, NY, Singapore
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 7.1
- Price/Book
- —
Growth
- Revenue
- -18.6%
- EPS
- +70.9%
- Free Cash Flow
- +157.0%
Profitability
- Gross Margin
- 40.8%
- Operating Margin
- -21.0%
- Net Margin
- -48.7%
- ROE
- 56.4%
- ROIC
- -21.9%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 1.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.